Sophia Hudson, P.C.

Since joining Kirkland, Sophia has been involved in the following transactions:

• AbbVie in its:
  
  • $83 billion acquisition of Allergan and related $30 billion offering of senior notes to fund the acquisition; the debt offering represented the largest corporate bond sale of 2019 and the fourth-largest in history 
  • exchange offers and consent solicitations for ~$22 billion of Allergan debt in connection with its acquisition of Allergan
• Affimed in multiple follow-on offerings of common stock totaling ~$200 million and in the establishment of an “At-the-Market” sales program
• Apax Partners and Warburg Pincus in the sale of $2.075 billion of senior notes to fund the $3.4 billion buy-out of Inmarsat
• Associated Materials in its $250 million offering of senior notes
• Awilhelmsen in its sale of more than $550 million of common stock of Royal Caribbean Cruises
• BCLS Acquisition Corp., a SPAC sponsored by Bain Capital Life Sciences, in its $125 million IPO
• Bristol Myers Squibb in its:
  
  • $90 billion acquisition of Celgene and related $19 billion offering of senior notes to fund the acquisition
  • exchange offers and consent solicitations for ~$19 billion of Celgene debt in connection with its acquisition of Celgene
  • $13.1 billion acquisition of MyoKardia and related $7 billion offering of senior notes to fund the acquisition
• Carlisle Companies in its $750 million offering of senior notes
• Colfax in its $3.2 billion acquisition of DJO Global
• Delphi Technologies in its $3.3 billion sale to BorgWarner
• Fox in its:
  
  • $440 million acquisition of Tubi
  • $1.2 billion offering of senior notes
• Huntsman International in its $750 million offering of senior notes
• InflaRx in its $50 million follow-on offering of common stock and in the establishment of an “At-the-Market” sales program
• Intelsat in its debt restructuring and in connection with its Chapter 11 bankruptcy
• J.C. Penney in its debt restructuring and in connection with its Chapter 11 bankruptcy
• KPS Capital Partners in its acquisition of AM General and related $600 million offering of senior notes to fund the buy-out
• loanDepot, Inc., the second largest retail non-bank lender in the United States and leading retail mortgage lender, in its IPO
• Montes Archimedes Acquisition Corp., a SPAC sponsored by Patient Square Capital, in its $400 million IPO
• Norwegian Cruise Line in its:
  
  • $850 million offering of senior notes
  • $832 million follow-on offering of common stock
  • $2.4 billion transaction involving four different capital markets products, the first-ever four-tranched marketed financing
  • $287.5 million follow-on offering of common stock, $750 million offering of senior notes and $400 million offering of exchangeable senior notes
• Pharvaris in its $80 million pre-IPO cross-over financing
• Pike Corp. in its:
  
  • majority investment by Lindsay Goldberg
  • $500 million offering of senior notes
• Rocket Software in its $500 million offering of senior notes
• TPG Real Estate Finance Trust in its:
  
  • sale of its $572 million debt securities portfolio to an undisclosed counterparty
  • up to $325 million investment from Starwood Capital
• Tupperware Brands in its cash tender offers to purchase up to $175 million aggregate principal amount of its outstanding senior notes
• United Airlines in its:
  • $5 billion funding from the U.S. Treasury under the CARES Act Payroll Support Program
  • $6.8 billion financing comprising of $3.8 billion of bonds and $3 billion of term loans secured by its MileagePlus loyalty program
• viagogo in its debt and preferred equity financings to fund its $4.05 billion acquisition of StubHub from eBay

Prior to joining Kirkland, Sophia represented the following public companies in their day-to-day SEC compliance, disclosure and governance matters:

• Affimed, Auris Medical, Bausch Health (f/k/a Valeant), Becton Dickinson, Biotie Therapies, EnteraBio, Heinz, InflaRx, Pernix, Prosensa and Warner Chilcott

Prior to joining Kirkland, Sophia represented issuers and underwriters in numerous debt offerings and related transactions, including in the following:

• Avadel Pharmaceuticals in its $143.7 million offering of exchangeable debt
• Bristol Myers Squibb in its cash tender offer for any and all of its outstanding notes due 2036 and 2038 and debentures due 2097
• Coach in its $1 billion debt offering to fund its acquisition of Kate Spade & Co.
• General Motors in multiple debt offerings totaling $6 billion
• General Motors Financial in multiple debt offerings totaling $15.7 billion
• Insulet in its $402.5 million offering of convertible debt
• The J. M. Smucker Co. in its $800 million debt offering to refinance existing debt
• Magellan Health in its $400 million debt offering to repay existing debt
• Medtronic Global Holdings and Medtronic in its concurrent debt offerings totaling $2 billion
• Merck in its €1 billion debt offering to repay existing debt and refinance shorter term maturity debt
• Pernix Therapeutics in its:
  
  • separate private exchange offers for its existing notes held by certain holders for new securities
  • series of refinancing transactions that are intended to improve liquidity, extend debt maturities and enable Pernix to create value for stakeholders
• Sucampo Pharmaceuticals in its $300 million offering of convertible debt
• Valeant Pharmaceuticals International in multiple debt offerings totaling $7.75 billion
• The Western Union Co. in its $400 million debt offering 

Davis Polk & Wardwell LLP

• Partner, 2014–2018
• Associate, 2006–2014